Tudor Brown, Former President of Cambridge-based ARM Holdings, Joins The Innovation Debate 2012, The Royal Society, 20th

   Tudor Brown, Former President of Cambridge-based ARM Holdings, Joins The
        Innovation Debate 2012, The Royal Society, 20th November 2012

  PR Newswire

  CHERTSEY, England, November 15, 2012

CHERTSEY, England, November 15, 2012 /PRNewswire/ --

  To watch the debate live register FREE today at www.innovationdebate.com

Tudor Brown , former President of Cambridge-based semiconductor giant ARM
Holdings, will join the distinguished panel of world-leading experts and
chairman Professor Jim Al-Khalili for The Innovation Debate 2012 , taking
place on 20 ^th November at 4pm, at the Royal Society in London, webcast live
at www.innovationdebate.com

Video: http://www.prnewswire.co.uk/news-releases/179434131.html

Together they will debate "How do we innovate in a time of austerity?" and
"Are we doing enough to nurture innovators of the future?"

Presenting his views on the current state of innovation, Tudor Brown - who
also previously sat on the UK Government Asia Task Force - said:

"The British have always been good at innovation and today this ability is
alive and well, despite what you read in the press. We now need to harness the
next generation of engineers and scientists to create winning products and
services, which are the lifeblood of this country as a trading nation."

Brown - a passionate believer in the UK's technological creativity and the
opportunities for British companies to achieve success through exporting -
will join fellow panellists who include: Professor Andre Geim , awarded the
Nobel Prize in 2010 for his ground-breaking work on Graphene, a one-atom-thick
material made of carbon; Professor Paul Workman , Deputy Chief Executive of
the Institute of Cancer Research; Professor Mariana Mazzucato , Professor in
Economics at the University of Sussex; Professor Paul Boyle , President of
Science Europe, which promotes the collective interests of European research
organisations and DRBeau Lotto , neuroscientist attached to University
College, London's Institute of Ophthalmology.

In a tough economic climate, innovation needs to remain the lifeblood of
science, technology and the economy. There is an urgent need to focus on how
best to promote and nurture innovation - today and in the future.

That is why The Innovation Debate 2012 - organised and funded by Astellas
Pharma Europe Ltd . - is bringing together influential and respected figures
from the worlds of science, technology, medicine, education, government,
industry and the media to discuss how best to encourage and nurture scientific
innovation. The aim of The Innovation Debate is to air crucial issues, draw
positive conclusions and to move the agenda forward.

Everyone - professionals in science and technology, students and the general
public - will have the opportunity to engage with The Innovation Debate
through online media, taking discussions far beyond the walls of the Royal

Join the Innovation Debate 2012

The Innovation Debate will encourage wider participation from the public and
science community via the website www.innovationdebate.com . Everyone will
have the opportunity to share their views on the critical challenges facing
science and innovation raised by The Innovation Debate and to submit a
question to the panel of experts. To watch the live webcast of the Debate from
4pm on 20 ^th November 2012, register today at www.innovationdebate.com

Join the debate now at www.innovationdebate.com and follow us on Twitter
@Innovatedebate #innovationdebate

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is the European headquarters
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. The organisation's focus
is to deliver outstanding R&D and marketing to continue growing in the world
pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21
affiliate offices located across Europe, the Middle East and Africa, an R&D
site and three manufacturing plants. The company employs approximately 4,300
staff across these regions. For more information about Astellas Pharma Europe,
please visit www.astellas.eu .

Contact: For further information, please contact: Mindy Dooa, Communications
Director, Astellas Pharma Europe Ltd., Tel: +44-(0)-203-379 8035 ,
Mobile:+44-(0)7826-912-339 , Email: mindy.dooa@astellas.com
Press spacebar to pause and continue. Press esc to stop.